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Abstract: Ketoconazole is listed among drugs that prolong QT interval and may increase the risk of torsade de pointes, a severe
ventricular arrhythmia. This compound has recently been approved for treatment of Cushing’s syndrome, a severe endocrine dis-
order. These patients harbour several risk factors for prolonged QT interval, for example hypokalaemia and left ventricular hyper-
trophy, but no study has evaluated whether administration of ketoconazole affects their QT interval. The aim of this study was
to assess the QT interval in patients with Cushing’s disease during long-term administration of ketoconazole. Electrocardiograms
from 15 patients with Cushing’s disease (12 women, 3 men, age: 37.8  2.66 years) on ketoconazole treatment (100 mg–
800 mg qd) for 1 month to 12 years were reviewed retrospectively. QT interval was measured and corrected for heart rate
(QTc). Measurements before and during ketoconazole treatment were compared and any abnormal QTc value recorded. Concur-
rent medical therapies were also documented. On average, QTc was superimposable before and during ketoconazole treatment
(393.2  7.17 versus 403.3  6.05 msec. in women; 424.3  23.54 versus 398.0  14.93 msec. in men, N.S.). QTc normal-
ized on ketoconazole in one man with prolonged QTc prior to treatment; no abnormal QTc was observed in any other patient
during the entire observation period, even during concurrent treatment with other QT-prolonging drugs. In conclusion, long-term
ketoconazole administration does not appear to be associated with significant prolongation of QT interval in patients with
Cushing’s disease. ECG monitoring can follow recommendations drawn for other low-risk QT-prolonging drugs with attention to
specific risk factors, for example hypokalaemia and drug interactions.
Prolongation of the electrocardiographic QT interval may be
due to administration of drugs that are known to prolong ven-
tricular repolarization, for example antiarrhythmic agents, as
well as non-cardiac drugs [1]. In fact, the pro-arrhythmic
potential of any new drug must be established prior to its use
in clinical practice [2]. Iatrogenic QT interval prolongation
predisposes to torsade de pointes, a severe ventricular arrhyth-
mia which may resolve spontaneously or, if prolonged, lead to
syncope and, possibly, cardiac arrest. Thus, drug-induced QT
prolongation is closely monitored, and lists of drugs known to
prolong QT interval are being continuously updated [3].
One such drug is ketoconazole, an imidazole derivative with
potent inhibitory effects on several cytochromes, including the
liver CYP3A4 enzyme. In fact, ketoconazole may interfere
with hepatic metabolism [4], thus lengthening plasma half-life
of known QT-prolonging drugs, for example antiarrhythmics,
antihistamines, antidepressants and antibiotics, resulting in QT
prolongation [5,6]. It is classified among low-risk QT-prolong-
ing drugs, that is, may increase the risk of torsade de pointes
if administered to patients at risk for QT interval prolongation
[3]. Clinical evidence on this side effect was collected during
the use of ketoconazole as an antifungal agent, usually at 50–
200 mg qd, for a few weeks at most. Ketoconazole as an
antimycotic has since been withdrawn, but it remains one of
the major drugs for Cushing’s syndrome, a rare endocrine dis-
order characterized by considerable morbidity due to excess
cortisol secretion. Ketoconazole inhibits adrenal steroidogene-
sis and is required in these patients to contain hypercortisolism
prior to surgery, after unsuccessful surgery and/or while await-
ing the effects of radiotherapy [7–9]; in this condition, keto-
conazole is administered at higher doses, for example 200–
1200 mg qd, and often for months or even years. After dec-
ades of off-label use [9,10], ketoconazole has been recently
approved by the European Medical Agency for treatment of
patients with Cushing’s syndrome [11] and is likely to achieve
a more widespread use.
We have recently observed a prolongation of the electrocar-
diographic QT interval in male patients with Cushing’s syn-
drome [12]; thus, these patients may incur in additional risk of
prolonged QT interval if administered ketoconazole. Safety of
ketoconazole administration may become a primary issue,
especially if other risk factors for QT interval prolongation,
for example hypokalaemia and left ventricular hypertrophy,
occur or additional QT-prolonging drugs are administered.
However, no study has yet evaluated whether prolongation of
QT interval occurs in patients with Cushing’s syndrome dur-
ing ketoconazole treatment. We therefore decided to analyse
electrocardiographic readings in patients with Cushing’s
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syndrome on ketoconazole in order to report on changes in
QT interval.
Patients and Methods
Study population. Fifteen patients treated with ketoconazole for
ACTH-dependent pituitary Cushing’s syndrome, that is, Cushing’s
disease (12 women, three men; age: 37.8  2.66 years; range: 23–
59 years), were studied. Nine patients were hypertensive and three
presented left ventricular hypertrophy as assessed by
echocardiography. Ketoconazole was administered prior to surgery in
five patients and after unsuccessful surgery or after relapse of
hypercortisolism in 10 patients. Length of treatment with
ketoconazole ranged from 1 month to 12 years, median 7 months;
dosage was 100–800 mg/daily, median 600 mg/daily (table 1).
Overall, analysis comprised 598 patient-months. Details of the three
patients on long-term ketoconazole treatment were as follows: patients
#3 and #12 had achieved partial control of hypercortisolism with
radiotherapy after surgical failure and were unwilling to undergo
adrenalectomy; patient #15 developed a stroke after relapse of
hypercortisolism and could not be submitted to further surgery/
radiotherapy. In all three patients, urinary free cortisol was within the
normal range on ketoconazole. Case history of the entire series
included cardiac disorders and any drug known to affect QT interval:
in detail, five patients were on antidepressive medication, and one
was administered glibenclamide; two had been briefly treated with
ciprofloxacin (table 1). The study was approved by the Ethical
Committee of our institution.
Electrocardiogram. Standard electrocardiograms had been performed
in patients on ketoconazole at various time-points over the years, in
keeping with our clinical surveillance practice. These tracings were
recovered and QT interval duration measured by a cardiologist blinded
to patients’ status. In detail, QT interval (lead II of the conventional
12-lead electrocardiogram) was measured in five non-consecutive
beats [13] and divided by the square root of the R-R interval
according to Bazett’s formula (QTc) [14]. Electrocardiographic
tracings were also reviewed for hypokalaemia-induced prominent U
waves. Normal values for QTc are <440 msec. for men and
<460 msec. for women. For statistical analysis, readings before
starting ketoconazole and from the last available ECG on
ketoconazole (see table 1 for length of follow-up) were compared.
Hormonal and biochemical evaluation. Urinary free cortisol (UFC),
ACTH and serum cortisol, as well as gonadal status, thyroid function
and serum electrolytes, were evaluated at baseline and during
ketoconazole treatment. UFC was measured after extraction by solid-
phase radioimmunoassay (DPC Coat-a-Count; Los Angeles, USA);
serum cortisol and plasma ACTH were measured by commercial
immunometric assays (Diasorin, Saluggia, Italy). TSH, free thyroid
hormones and androgens were assayed by electrochemiluminescence
(ECLIA; Roche Diagnostics, Monza, Italy). Clinical chemistry
platform was used to determine serum electrolytes as well as routine
clinical analyses (Hitachi 917; Roche Diagnostics, Monza, Italy).
Normal values in our laboratory for UFC, serum cortisol and plasma
ACTH are 10–80 lg/24 hr, 5–25 lg/dL and 10–50 pg/mL,
respectively; total testosterone should be comprised within 9.9–
27.8 nmol/L in adult males.
Statistical analysis. Quantitative values were compared by
Wilcoxon’s test for paired data. Statistical significance was accepted at
p < 0.05. Data are described as mean  S.E.M.
Table 1.
Features of patients with Cushing’s disease on ketoconazole.
Baseline On ketoconazole
Pt # Sex/Age LVH Kalaemia QTc
QT-prolonging
drugs Disease phase Dose, mg Length Kalaemia QTc
QT-prolonging
drugs
1 M/36 No 3.9 436 Prior to TSS 800 5 3.8 426
2 M/30 No 4.4 379 TSS failure 600 24 4.5 393
3 M/23 Yes 3.15 458 TSS failure;
after RT
100 132 3.8 375
4 F/55 Yes 3.7 418 Fluoxetine 20 mg TSS failure 200 60 4.0 406 Fluoxetine 20 mg
5 F/42 No 4.7 408 Paroxetine 20 mg Prior to TSS 400 6 5.3 431 Paroxetine 20 mg
6 F/31 No 3.9 372 Prior to TSS 600 7 4.5 377
7 F/40 No 3.9 424 Prior to TSS 600 1 4.4 408
8 F/34 No 4.1 433 Prior to TSS 600 6 3.6 440
9 F/59 Yes 3.5 391 Citalopram 20 mg TSS failure 400 5 3.7 388 Citalopram 20 mg
Glibenclamide 15 mg Glibenclamide 15 mg
Ciprofloxacin 1 g
(1 week)
10 F/34 No 4.2 402 TSS failure;
after RT
600 7 4.0 392 Escitalopram 20 mg
11 F/27 No 4.4 367 TSS failure;
after RT
400 18 4.4 388
12 F/51 No 4.5 368 TSS failure;
after RT
400 132 4.4 375 Ciprofloxacin 1 g
(1 week)
13 F/29 No 3.8 375 Relapse 600 36 3.8 408
14 F/41 No 4.1 360 TSS failure 800 12 4.3 400
15 F/35 No 3.9 402 Relapse 400 144 3.3 450 Paroxetine 20 mg
LVH, left ventricular hypertrophy as assessed by echocardiography; TSS, transsphenoidal surgery; RT, radiotherapy. Length of ketoconazole treat-
ment is given in months. QTc values on ketoconazole represent the last available measure during treatment. Unless otherwise stated, treatment with
known QT-prolonging drugs was protracted over years. Daily dosage is given for all drugs. Data in bold represent abnormal values.
© 2015 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the
Publication of BCPT (former Nordic Pharmacological Society).
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Results
In all patients but one, patient #3, QTc values were within the
normal range prior to ketoconazole administration. Further,
QTc measurements were comprised within the normal range
in all patients during ketoconazole administration, and no
arrhythmic or otherwise acute cardiac event was reported over
the entire 598-patient-month observation period. On average,
QTc values before and at the last available reading during
ketoconazole treatment were superimposable in both sexes
(393.2  7.17 versus 405.2  6.96 msec. in women and
424.3  23.54 versus 398.0  14.93 msec. in men, respec-
tively, both NS).
In patient #3, QTc was prolonged prior to starting ketocona-
zole (458 msec.) and then normalized and remained within the
normal range throughout ketoconazole treatment for 11 years
(range 367–410 msec., 375 msec. at last measurement;
table 1). Of note, markedly abnormal QTc had been registered
in this patient during the active disease phase (485 msec.)
which then shortened upon partial remission of hypercorti-
solism with transsphenoidal surgery (458 msec.). The patient
presented left ventricular hypertrophy (LVMi 63.2 g/m2; nor-
mal range <50 g/m2), modest hypokalaemia (3.15 mEq/L) and
subnormal testosterone levels (5.84 nmol/L) at diagnosis; ven-
tricular hypertrophy ameliorated (LVMi 55.8 g/m2) after sur-
gery, while biochemical alterations normalized and remained
stable during treatment with ketoconazole: potassium values
ranged from 3.8 to 4.15 mEq/L and testosterone concentra-
tions from 18.8 to 19.9 nmol/L.
Several patients were administered QT-prolonging drugs,
for example antibiotics, psychotropic drugs and oral hypogly-
caemic agents (table 1), while on ketoconazole without pro-
longation of the QT interval. Notably, no changes in QTc
were observed in patients treated with ketoconazole for 11 and
12 years (patients #12 and #15) even during concomitant
administration of ciprofloxacin for 1 week and paroxetine for
2 years, respectively (table 1). Patient #15 also developed
transitory hypokalaemia (3.3 mEq/L) while on ketoconazole,
but her QTc remained below 460 msec. (fig. 1).
No significant elevation of liver enzymes, that is increase
greater than 3 times the upper limit of the normal range, as
per the National Cancer Institute-Common Toxicology Criteria
Adverse Events version 4.03 (NCI-CTCAE v.4.03 published
in June 2010), was observed on ketoconazole in any patient.
Discussion
Ketoconazole is classified among low-risk QT interval-pro-
longing drugs [3] and is thus weakly associated with the risk
of torsade de pointes, the most severe ventricular arrhythmia
resulting from prolonged QT interval. Ketoconazole is consid-
ered among QT-prolonging drugs as it is known to inhibit, in
addition to steroidogenic CYP enzymes [15], also hepatic
CYP3A4 [5] thereby prolonging half-life of drugs metabolized
by this enzyme, for example antiarrhythmics, antihistamines,
antidepressants and antibiotics. In fact, co-administration of
ketoconazole has been shown to prolong QT interval in
healthy volunteers administered antihistamines such as terfe-
nadine [16,17], loratadine or ebastine [18,19], domperidone –
a gastrointestinal stimulant [20] – or the macrolide telithromy-
cin [21]. Increases in QT interval reported in these studies
range from 10 msec. with ebastine or telithromycin, 20 mm
with domperidone and up to 70 msec. with terfenadine
[16,18,21,22]. In addition to these studies in healthy volun-
teers, single-case reports described prolonged QT interval, tor-
sade de pointes and syncopal episodes in patients treated with
ketoconazole and terfenadine, astemizole or cetirizine [23–26].
Ketoconazole may also have a direct effect on QT interval.
In fact, experimental studies have shown that ketoconazole
blocks cardiac potassium HERG (Ikr) channels [27–29] and
alters HERG protein channel trafficking [28], thus prolonging
action potential. Further, ketoconazole may slow inactivation
of voltage-gated L-type calcium channels [30]. Overall, how-
ever, thorough QT (TQT) studies [2] in healthy volunteers
demonstrated that ketoconazole had a slight, non-significant
effect on QT interval, that is ~8 msec. [18,22,31].
Ketoconazole has been withdrawn as an antifungal but is
still in use in Cushing’s syndrome, a severe endocrine disorder
characterized by excess cortisol secretion. First-choice therapy
for this condition is surgical removal of the causative lesion,
but medical treatment is frequently required prior to surgery,
after unsuccessful surgery and/or while awaiting the effects of
radiotherapy [7–9]. Dosage of ketoconazole in this setting is
higher than in mycotic infections (e.g. 400–1200 mg qd versus
50–200 mg qd) [9] and treatment carried out for longer peri-
ods of time, often months or even years if there are no viable,
alternative treatment options. In Cushing’s syndrome, keto-
conazole has been used off-label for decades and was just
recently approved by the European Medicines Agency [11].
The recent sanctioning is likely to lead to a greater use of this
compound, but no data on its possible untoward effect on QT
interval in patients with Cushing’s syndrome are as yet avail-
able.
Our study now shows that administration of ketoconazole
in patients with Cushing’s disease is not associated with











Fig. 1. QTc interval in patient #15 treated with 400 mg ketoconazole
qd for 12 years. Baseline measurement is shown as empty circle; filled
circles indicate measurements on ketoconazole. Shaded area indicates
normal range. Transitory hypokalaemia was registered at 10-year eval-
uation (3.3 mEq/L). Paroxetine 20 mg qd was added in the last
2 years.
© 2015 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the
Publication of BCPT (former Nordic Pharmacological Society).
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significant QT interval prolongation. We even observed nor-
malization of QT interval in the patient with prolonged QTc
prior to efficacious ketoconazole treatment. It is worth recall-
ing that ketoconazole is listed among drugs at conditional risk
of torsade de pointes, thus determined by drug overdose,
drug–drug interactions or when administered to high-risk indi-
viduals. Thus, unless these conditions are met, ketoconazole is
weakly associated with risk of torsade de pointes.
As regards drug overdosage, 400 mg ketoconazole daily
was administered for up to 12 years without significant QTc
interval prolongation. Half-life of ketoconazole ranges from 2
to 10 hr with almost complete hepatic metabolism and excre-
tion in faeces, and drug accumulation does not appear to occur
during prolonged administration [32,33].
Conversely, drug interactions might represent a problem
during long-term administration as these patients may necessi-
tate additional medical therapy – possibly comprising other
drugs at risk of QT interval prolongation such as antidepres-
sants, antidiabetics or antibiotics over time. In our series, this
indeed occurred but was not associated with significant QTc
prolongation. Of note, while significant QT prolongation has
been reported during co-administration of ketoconazole and
drugs with known risk of torsade de pointes [23–25], not all
associations lead to relevant QT prolongation [34,35]. Further,
experimental studies showed that sequential administration of
Ikr blockers, such as ketoconazole and domperidone, may
result in competitive antagonism rather than potentiation of
the HERG channel [36].
Likelihood of torsade de pointes on ketoconazole is higher
in patients with hypokalaemia and left ventricular hypertrophy,
both conditions frequent in Cushing’s syndrome. Indeed, we
recently reported a prolongation of QT interval in male
patients with Cushing’s syndrome [12], linked in part to hypo-
kalaemia. Low testosterone levels also appeared to contribute
to prolonged QTc in men with Cushing’s disease, an observa-
tion which is in keeping with the role of testosterone on QT
interval duration [37] and the high prevalence of abnormal
QTc measurements in hypogonadal male individuals [38,39].
One patient of the present series, a man with prolonged QTc
interval at initial evaluation, presented both hypokalaemia and
hypogonadism at the time. Surgery led to partial remission of
hypercortisolism and shortening of QT interval which, how-
ever, remained abnormal. Treatment with ketoconazole was
initiated leading to containment of excess cortisol secretion
and normalization of testosterone and potassium levels. QT
interval shortened further on ketoconazole and remained
within the normal range throughout the entire 11-year treat-
ment. Similarly, QT interval was normal in all patients well
controlled with ketoconazole, even if other QT interval-pro-
longing drugs were co-administered. This indicates that admin-
istration of ketoconazole to patients who present prolonged
QT interval secondary to a given, acquired disorder does not
interfere with normalization of QT interval if the underlying
cause is resolved. This finding tallies with the observation that
normalization of prolonged QT interval may occur during effi-
cacious treatment of acromegaly by octreotide, a somatostatin
analogue listed among agents at possible risk of torsade de
pointes. In fact, abnormal QT interval measurements decreased
during octreotide administration in these patients, in parallel
with amelioration of ventricular hypertrophy [40].
Lastly, it is worth mentioning that our study – albeit a small
series – conforms with Clinical Trial Evaluation requirements
for negative TQT studies, that is collection of baseline and
periodic on-therapy ECG in accordance with current practices
in a given therapeutic field [2,41]. In the present case, the lat-
ter encompasses repeat ECG assessments on ketoconazole and
close surveillance of patients who develop electrolyte abnor-
malities or require concomitant administration of known QT-
prolonging drugs. Once these factors are taken into due
account, monitoring of patients with Cushing’s disease on
ketoconazole can follow recommendations for any drug at low
risk of QT prolongation. Indeed, as discussed above, control
of hypercortisolism with ketoconazole is associated with reso-
lution of factors which may increase risk of QT prolongation
in patients with Cushing’s disease per se, for example hypog-
onadism and hypokalaemia.
In conclusion, our study shows that long-term ketoconazole
administration to patients with Cushing’s disease is not associ-
ated with significant QT interval prolongation. Our observa-
tion provides significant safety information on the use of
ketoconazole in these patients. ECG surveillance during keto-
conazole treatment in these patients can follow recommenda-
tions as for any low-risk QT-prolonging drug [42].
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